Twist Bioscience Co. (NASDAQ:TWST) COO Sells $10,440.11 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 229 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $45.59, for a total value of $10,440.11. Following the transaction, the chief operating officer now owns 274,466 shares in the company, valued at $12,512,904.94. The trade was a 0.08 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Patrick John Finn also recently made the following trade(s):

• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total transaction of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The shares were sold at an average price of $43.09, for a total value of $97,426.49.

Twist Bioscience Trading Down 6.0 %

NASDAQ:TWST traded down $2.89 during trading hours on Tuesday, reaching $45.62. 814,483 shares of the company were exchanged, compared to its average volume of 657,996. The firm has a market cap of $2.71 billion, a PE ratio of -12.67 and a beta of 1.85. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The stock’s 50-day moving average is $46.16 and its 200-day moving average is $46.51.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on TWST shares. Robert W. Baird raised their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, November 19th. Leerink Partners increased their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Wolfe Research started coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Evercore ISI lifted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.90.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience during the 3rd quarter valued at approximately $43,992,000. Point72 Asset Management L.P. increased its stake in Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after acquiring an additional 613,057 shares during the last quarter. Fred Alger Management LLC raised its position in Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after purchasing an additional 575,080 shares during the period. State Street Corp lifted its stake in shares of Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.